A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy. The main purpose of the Study is to analyze the safety (to find out how safe or toxic a treatment is to appropriately manage the risks) and efficacy (to find out how effective a treatment is) of bexmarilimab combined with doxorubicin in participants who have STS.

Trial Details

NCT ID
NCT07460986
Phase
PHASE1 / PHASE2
Sponsor
MedSIR
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • bexmarilimab
  • Doxorubicin
Locations (sample)
  • Badalona, Spain|41.45004,2.24741
  • Barakaldo, Spain|43.29639,-2.98813
  • Barcelona, Spain|41.38879,2.15899
  • Madrid, Spain|40.4165,-3.70256
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Participant, or legal representative (if applicable), must be capable to understand the purpose of the Study and have signed written informed conse…
  • Female or male participants ≥ 18 years of age at the time of signing ICF.
  • For phase Ib (dose escalation):
  • Histologically documented metastatic STS with no more than 3 lines of treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →